OLB) has secured a key regulatory boost from the US authorities for a drug it is developing to prevent a dangerous complication linked to advanced cancer treatments. The London-listed biotech group said on Tuesday that the Food and Drug Administration had granted Orphan Drug Designation to POLB 001, an experimental treatment designed to protect patients from a condition known as cytokine release syndrome (CRS). 